This workshop on Oct 9th. had been cancelled due to the Government Shutdown and will be rescheduled at a later date.
With Fall approaching, everyone is preparing for their favorite things whether that's football season, pumpkin carving, or more reasonable temperatures in Central Maryland. Fall is also a great time for the Small Business Innovation Research grant program throughout National Institutes of Health. In partnership with the NIH, BioHealth Innovation is sponsoring a fall gathering to talk about SBIR awards.
It's useful to hear directly from NIH program officials on the current funding priorities per Institute. We have assembled program leads from NHLBI, NIAID, and NCI who can provide small businesses with more insight into their SBIR programs. They will also be available for one-on-one consultations at the conclusion of the event.
Wednesday, October 9th, 1:00pm – 4:00pm (EDT)
155 Gibbs Street, 6th Floor
Rockville, MD 20850
(Overlooking Rockville Town Center)
- Hear from the largest SBIR awarding Institutes on current funding priorities.
- Meet one-on-one with program managers regarding your current project.
- Learn of SBIR assistance provided by BioHealth Innovation
|1:00 pm||Welcome and Introductions: BioHealth Innovation
Ethan Byler, Director, Innovation Programs
|Institute Remarks: SBIR Program Directors|
National Cancer Institute
National Heart Lung & Blood Institute
National Institute of Allergy & Infectious Diseases
|2:15pm||Open Networking Session & Refreshments|
One on one Discussion Session with Small Businesses
NATIONAL HEART, LUNG AND BLOOD INSTITUTE (NHLBI):
Passive MRI Cardiovascular Guidewire; MRI Myocardial Needle Injection Catheter; Transcatheter Pulmonary Artery Resist; Value of Information Models for Clinical Trial Assessment; Development of Molecular Imaging Agents and Methods to Detect High Risk Atherosclerotic Plaque; Tools for Educating Children About Clinical Research.
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID):
Biomedical Methods To Quantify Adherence To Prevention Clinical Trial Study ¬ Products and Strategies; Simple, Inexpensive Assay for Five Common HIV Resistance Mutations; Capreomycin: Formulation for Oral Delivery; Adjuvant Development.
NATIONAL CANCER INSTITUTE (NCI):
Development of Novel Therapeutic Agents that Target Cancer Stem Cells; Reformulation of Failed Chemotherapeutic Drugs; Validation of 3D Human Tissue Culture Systems that Mimic the Tumor Microenvironment; Proteomic Analysis of Single Cells Isolated from Solid Tumors; Generation of Site-Specific Phospho-Threonine Protein Standards for use in Cancer Assays; Development of a Biosensor-Based Core Needle Tumor Biopsy Device; Development of Radiation Modulators for Use During Radiotherapy; Software Tools for the Development of Environmental Measures Related to Cancer Health Behaviors and Resources.